I realized that my seed of a wish to witness change in people's experience with cancer was blossoming before my eyes. Just within my relatively short lifetime, we have evolved in opportunities and options, enabling people with cancer to have a better quality of life.
This groundbreaking, earth-shaking development in health care of targeted molecular treatments and companion diagnostics will change the treatment you are offered in a way that hasn't occurred since blood typing for transfusion, anesthesia and antibiotics all made surgery really possible.
In order to succeed we will also have to radically change the way we practice medicine. Matching macroscopic symptoms with standardized drugs just won't do. Each cancer patient is a new scientific problem.
Unlike the treatment of cancer, the future of personalized drug selection in treating hypertension is not likely to result from filling in a genetic map. It lies instead in understanding better, and making better use of, the clinical clues that can guide us.
In this era of global political revolution, fueled by an ongoing communications technology revolution, there is a quiet but equally profound revolution afoot in health care. It's called, simply, personalized medicine.
Personalized psychiatric diagnosis has great promise and may be one of the few ways out of the current impasse -- the constant flow of group mean studies giving non-replicated or barely-significant differences.
The recent jobs report from the Department of Labor raises an important question: Is the expansion within the health care industry a good thing for our economy and nation, or is it an emerging bubble that will inevitably burst?
Personalized medicine is an idea that someday we will all enjoy customized medical care that keeps us healthier. In the meantime, we're stuck with cookie-cutter predictions and trial-and-error treatments.